Peter J Hoskin1, Amy A Kirkwood2, Bilyana Popova2, Paul Smith2, Martin Robinson3, Eve Gallop-Evans4, Stewart Coltart5, Timothy Illidge6, Krishnaswamy Madhavan7, Caroline Brammer8, Patricia Diez9, Andrew Jack10, Isabel Syndikus11. 1. Mount Vernon Cancer Centre, Northwood, Middlesex, UK. Electronic address: peterhoskin@nhs.net. 2. Cancer Research UK and UCL Cancer Trials Centre, London, UK. 3. Weston Park Hospital, Sheffield, UK. 4. Velindre Hospital, Cardiff, UK. 5. Kent and Canterbury Hospital, Canterbury, UK. 6. Christie Hospital, Manchester, UK. 7. Southend General Hospital, Southend, UK. 8. New Cross Hospital, Wolverhampton, West Midlands, UK. 9. Mount Vernon Cancer Centre, Northwood, Middlesex, UK. 10. Leeds General Infirmary, Leeds, UK. 11. Clatterbridge Centre for Oncology, WirralI, UK.
Abstract
BACKGROUND: Follicular lymphoma has been shown to be highly radiosensitive with responses to doses as low as 4 Gy in two fractions. This trial was designed to explore the dose response for follicular lymphoma comparing 4 Gy in two fractions with 24 Gy in 12 fractions METHODS: FORT is a prospective randomised, unblinded, phase 3 non-inferiority study comparing radiotherapy given as 4 Gy in two fractions with a standard dose of 24 Gy in 12 fractions. Entry criteria included all patients aged over 18 years, having local radiotherapy for radical or palliative local control, with follicular lymphoma or marginal zone lymphoma, who had received no previous treatment for at least 1 month before. The primary outcome was time to local progression analysed on an intention-to-treat basis. Randomisation was centralised through the Cancer Research UK and University College London Cancer Trials Centre. Radiotherapy target sites were randomised (1:1) with minimisation stratified by histology (follicular lymphoma vs marginal zone lymphoma), treatment intent (palliative or curative) and centre. This trial is registered with ClinicalTrials.gov number, NCT00310167. FINDINGS:299 sites were randomly assigned to 24 Gy and 315 sites to 4 Gy between April 7, 2006, and June 8, 2011, at 43 centres in the UK. After a median follow-up of 26 months (range 0·39-75·4), 91 local progressions had been recorded (21 in the 24 Gy group and 70 in the 4 Gy group). Time to local progression with 4 Gy was not non-inferior to 24 Gy (hazard ratio 3·42, 95% CI 2·09-5·55, p<0·0001). Eight (3%) of 282 patients in the 24 Gy group and four (1%) of 300 in the 4 Gy group had acute grade 3-4 toxic effects. Four (1%) patients in the 24 Gy group and four (1%) patients in the 4 Gy group had late toxic effects. Mucositis was the most common event in the 24 Gy group (two patients with acute mucositis and two with late mucositis; all grade 3) and was not reported in the 4 Gy group. The most common acute effect was pain at the site of irradiation (two patients in the 4 Gy group, one patient in the 24 Gy group; all grade 3), and the most common late effect was fatigue (two patients in the 4 Gy group, one patient in the 24 Gy group; all grade 3). INTERPRETATION: 24 Gy in 12 fractions is the more effective radiation schedule for indolent lymphoma and should be regarded as the standard of care. However, 4 Gy remains a useful alternative for palliative treatment. FUNDING: Cancer Research UK.
RCT Entities:
BACKGROUND:Follicular lymphoma has been shown to be highly radiosensitive with responses to doses as low as 4 Gy in two fractions. This trial was designed to explore the dose response for follicular lymphoma comparing 4 Gy in two fractions with 24 Gy in 12 fractions METHODS: FORT is a prospective randomised, unblinded, phase 3 non-inferiority study comparing radiotherapy given as 4 Gy in two fractions with a standard dose of 24 Gy in 12 fractions. Entry criteria included all patients aged over 18 years, having local radiotherapy for radical or palliative local control, with follicular lymphoma or marginal zone lymphoma, who had received no previous treatment for at least 1 month before. The primary outcome was time to local progression analysed on an intention-to-treat basis. Randomisation was centralised through the Cancer Research UK and University College London Cancer Trials Centre. Radiotherapy target sites were randomised (1:1) with minimisation stratified by histology (follicular lymphoma vs marginal zone lymphoma), treatment intent (palliative or curative) and centre. This trial is registered with ClinicalTrials.gov number, NCT00310167. FINDINGS: 299 sites were randomly assigned to 24 Gy and 315 sites to 4 Gy between April 7, 2006, and June 8, 2011, at 43 centres in the UK. After a median follow-up of 26 months (range 0·39-75·4), 91 local progressions had been recorded (21 in the 24 Gy group and 70 in the 4 Gy group). Time to local progression with 4 Gy was not non-inferior to 24 Gy (hazard ratio 3·42, 95% CI 2·09-5·55, p<0·0001). Eight (3%) of 282 patients in the 24 Gy group and four (1%) of 300 in the 4 Gy group had acute grade 3-4 toxic effects. Four (1%) patients in the 24 Gy group and four (1%) patients in the 4 Gy group had late toxic effects. Mucositis was the most common event in the 24 Gy group (two patients with acute mucositis and two with late mucositis; all grade 3) and was not reported in the 4 Gy group. The most common acute effect was pain at the site of irradiation (two patients in the 4 Gy group, one patient in the 24 Gy group; all grade 3), and the most common late effect was fatigue (two patients in the 4 Gy group, one patient in the 24 Gy group; all grade 3). INTERPRETATION: 24 Gy in 12 fractions is the more effective radiation schedule for indolent lymphoma and should be regarded as the standard of care. However, 4 Gy remains a useful alternative for palliative treatment. FUNDING: Cancer Research UK.
Authors: Mary-Elizabeth M Percival; Ryan C Lynch; Anna B Halpern; Mazyar Shadman; Ryan D Cassaday; Chaitra Ujjani; Andrei Shustov; Yolanda D Tseng; Catherine Liu; Steven Pergam; Edward N Libby; Bart L Scott; Stephen D Smith; Damian J Green; Ajay K Gopal; Andrew J Cowan Journal: JCO Oncol Pract Date: 2020-05-05
Authors: Michael S Binkley; Jessica L Brady; Carla Hajj; Monica Chelius; Karen Chau; Alex Balogh; Mario Levis; Andrea Riccardo Filippi; Michael Jones; Sameera Ahmed; Michael MacManus; Andrew Wirth; Masahiko Oguchi; Anders Krog Vistisen; Therese Youssef Andraos; Andrea K Ng; Berthe M P Aleman; Seo Hee Choi; Youlia M Kirova; Sara Hardy; Gabriele Reinartz; Hans T Eich; Scott V Bratman; Louis S Constine; Chang-Ok Suh; Bouthaina Dabaja; Tarec C El-Galaly; David C Hodgson; Umberto Ricardi; Joachim Yahalom; N George Mikhaeel; Richard T Hoppe Journal: Int J Radiat Oncol Biol Phys Date: 2019-03-08 Impact factor: 7.038
Authors: Gabriele Reinartz; Regina P Pyra; Georg Lenz; Rüdiger Liersch; Georg Stüben; Oliver Micke; Kay Willborn; Clemens F Hess; Andreas Probst; Rainer Fietkau; Ralf Jany; Jürgen Schultze; Christian Rübe; Carsten Hirt; Wolfgang Fischbach; Martin Bentz; Severin Daum; Christiane Pott; Markus Tiemann; Peter Möller; Andreas Neubauer; Martin Wilhelm; Normann Willich; Wolfgang E Berdel; Hans T Eich Journal: Strahlenther Onkol Date: 2019-03-11 Impact factor: 3.621
Authors: Joshua W D Tobin; Gabrielle Rule; Katherine Colvin; Lourdes Calvente; David Hodgson; Stephen Bell; Chengetai Dunduru; James Gallo; Erica S Tsang; Xuan Tan; Jonathan Wong; Jessica Pearce; Robert Campbell; Shao Tneh; Sophie Shorten; Melissa Ng; Tara Cochrane; Constantine S Tam; Emad Abro; Eliza Hawkes; Georgina Hodges; Roopesh Kansara; Dipti Talaulikar; Michael Gilbertson; Anna M Johnston; Kerry J Savage; Diego Villa; Kirk Morris; Sumi Ratnasingam; Wojt Janowski; Robert Kridel; Chan Y Cheah; Michael MacManus; Nicholas Matigian; Peter Mollee; Maher K Gandhi; Greg Hapgood Journal: Blood Adv Date: 2019-10-08